Bright Minds Biosciences (DRUG) Liabilities and Shareholders Equity (2020 - 2026)

Bright Minds Biosciences' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $227.8 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 478.79% year-over-year to $227.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $392.2 million (up 334.67% YoY) and the FY2025 annual result came in at $61.3 million, up 1270.81% from the prior year.
• Liabilities and Shareholders Equity was $227.8 million for Q1 2026 at Bright Minds Biosciences, up from $65.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $227.8 million in Q1 2026 and bottomed at $4.5 million in Q3 2024.
• A 5-year average of $32.1 million and a median of $8.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity tumbled 61.72% — and 2025, when it surged 1270.81%.
• Bright Minds Biosciences' Liabilities and Shareholders Equity stood at $8.5 million in 2022, then slumped by 40.55% to $5.1 million in 2023, then soared by 726.38% to $41.8 million in 2024, then surged by 55.89% to $65.2 million in 2025, then surged by 249.52% to $227.8 million in 2026.
• Business Quant data shows DRUG's Liabilities and Shareholders Equity at $227.8 million in Q1 2026, $65.2 million in Q4 2025, and $61.3 million in Q3 2025.